Alnylam's $250 million investment will enhance its Norton, Massachusetts facility with an enzymatic ligation platform to meet global RNAi therapeutics demand. The expansion supports Alnylam's pipeline ...
New platform is expected to substantially increase manufacturing capacity and lower production costs, enabling investment in expanding pipeline FDA has accepted Alnylam’s enzymatic ligation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback